APHS

APHS is a specific and covalent COX-2 inhibitor with neuroprotective effects. COX-2 is a prostaglandin (PG) synthetase overexpressed in colorectal cancer (CRC) and has pleiotropic cancer-promoting effects. APHS modifies COX-2 by acetylating the active site (serine 516), thereby inhibiting prostaglandin production. The neuroprotective activity of APHS is inhibited by prostaglandin E2. APHS also co-inhibits the WNT pathway, an anti-tumor mechanism in addition to COX-2 inhibition[1][2].

Product Specifications

CAS Number

[209125-28-0]

UNSPSC

12352005

Hazard Statement

H225-H319-H336

Target

COX; Wnt

Type

Reference compound

Related Pathways

Immunology/Inflammation; Stem Cell/Wnt

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/aphs.html

Concentration

38.11 mM * 100 μL in Methyl acetate

Purity

99.0

Solubility

10 mM in DMSO

Smiles

CCCCC#CCSC1=CC=CC=C1OC(C)=O

Molecular Formula

C15H18O2S

Molecular Weight

262.37

Precautions

P210-P233-P240-P241-P242-P243-P261-P264-P271-P280-P303+P361+P353-P304+P340-P305+P351+P338-P370+P378-P403+P233-P403+P235-P405-P501

References & Citations

[1]Carlson NG. Neuroprotection of cultured cortical neurons mediated by the cyclooxygenase-2 inhibitor APHS can be reversed by a prostanoid. J Neurosci Res. 2003 Jan 1;71 (1) :79-88.|[2]Humar B, McNoe L, Dunbier A, Heathcott R, Braithwaite AW, Reeve AE. Heterogeneous gene expression changes in colorectal cancer cells share the WNT pathway in response to growth suppression by APHS-mediated COX-2 inhibition. Biologics. 2008 Jun;2 (2) :329-37.